U.S. markets close in 1 hour 27 minutes
  • S&P 500

    4,419.62
    +16.96 (+0.39%)
     
  • Dow 30

    34,974.15
    +181.48 (+0.52%)
     
  • Nasdaq

    14,879.41
    +98.88 (+0.67%)
     
  • Russell 2000

    2,232.14
    +35.82 (+1.63%)
     
  • Crude Oil

    68.97
    +0.82 (+1.20%)
     
  • Gold

    1,803.20
    -7.30 (-0.40%)
     
  • Silver

    25.23
    -0.24 (-0.93%)
     
  • EUR/USD

    1.1843
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.2150
    +0.0310 (+2.62%)
     
  • GBP/USD

    1.3935
    +0.0050 (+0.36%)
     
  • USD/JPY

    109.7530
    +0.2850 (+0.26%)
     
  • BTC-USD

    40,834.13
    +1,250.95 (+3.16%)
     
  • CMC Crypto 200

    1,003.85
    +27.96 (+2.86%)
     
  • FTSE 100

    7,120.43
    -3.43 (-0.05%)
     
  • Nikkei 225

    27,728.12
    +144.04 (+0.52%)
     

AbbVie, Lilly Atopic Dermatitis Treatments Hit With Further Delays With FDA

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • AbbVie Inc (NYSE: ABBV) and Eli Lilly And Co (NYSE: LLY) will have to keep waiting for a chance for their JAK inhibitors in atopic dermatitis to see the market.

  • The companies separately said on Friday that the FDA again delayed decisions over their applications for Rinvoq (upadacitinib) and Olumiant (baricitinib) in moderate to severe atopic dermatitis.

  • Neither provided an updated timeline for the agency's decision.

  • Federal regulators are working through safety concerns shrouding Pfizer's JAK inhibitor Xeljanz after a post-marketing study earlier this year turned up risks for dangerous heart side effects and cancer.

  • Olumiant, Xeljanz, and Rinvoq already bear boxed warnings about serious infections, blood clots, and cancers.

  • As Xeljanz was the first of the class to enter the market, the FDA required Pfizer to conduct a long-term post-marketing study on its product to evaluate those risks further.

  • Friday's FDA delay marks the second holdup for Eli Lilly- Incyte Corporation (NASDAQ: INCY) and AbbVie's eczema medicines following an initial setback in April.

  • Price Action: LLY stock +0.27% at $232.09, INCY stock -0.94% at $79.25, and ABBV shares +0.44% at $117.69 during the market session on the last check Friday.

  • Related content: Benzinga's Full FDA Calendar.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.